What is the market capitalization of 20/20 Biolabs, Inc.?

20/20 Biolabs, Inc. (AIDX) has a market capitalization of approximately 8,913,684 USD.

Where can I buy AIDX in Canada?

AIDX can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

AIDX

20/20 Biolabs, Inc.

20/20 Biolabs, Inc. (AIDX) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 9 million USD (micro-cap).

Details

Price0.84 USD

Market cap8.91 M USD

Payout ratio0.00%

ROE-241.59%

Debt / Equity33.57%

SectorHealthcare

Website2020biolabs.com

Updated a few minutes ago

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.